{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Multiple+Myeloma&page=18", "query": { "condition": "Relapsed, Refractory Multiple Myeloma", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 865, "total_pages": 87, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Multiple+Myeloma&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Multiple+Myeloma&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T18:54:17.878Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05182073", "title": "FT576 in Subjects With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Myeloma" ], "interventions": [ { "name": "FT576 (Allogenic CAR NK cells with BCMA expression)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2021-11-10", "completion_date": "2024-10-18", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-11-15T18:54:17.878Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Duarte, California • Denver, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05182073" }, { "nct_id": "NCT00898612", "title": "Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2008-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-03-10", "last_synced_at": "2026-11-15T18:54:17.878Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00898612" }, { "nct_id": "NCT01575925", "title": "Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Renal Impairment" ], "interventions": [ { "name": "4 mg Oral POM + 40 mg Oral DEX", "type": "DRUG" }, { "name": "2 mg Oral POM + 40 mg Oral DEX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2012-06-01", "completion_date": "2018-08-07", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-11-15T18:54:17.878Z", "location_count": 7, "location_summary": "Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01575925" }, { "nct_id": "NCT04640779", "title": "Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Recurrent Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Refractory Histiocytic and Dendritic Cell Neoplasm", "Refractory Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Choline Salicylate", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2021-02-08", "completion_date": "2025-11-19", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-15T18:54:17.878Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04640779" }, { "nct_id": "NCT00027560", "title": "Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 51, "start_date": "2001-07", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2013-01-07", "last_synced_at": "2026-11-15T18:54:17.878Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027560" }, { "nct_id": "NCT04484623", "title": "Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2020-10-01", "completion_date": "2029-06-25", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-11-15T18:54:17.878Z", "location_count": 5, "location_summary": "Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04484623" }, { "nct_id": "NCT05332054", "title": "Long-Term Follow-up Study", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma, Non-Hodgkin", "Relapsed Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Lymphoma", "B Cell Lymphoma", "B-Cell Non-Hodgkin's Lymphoma", "Hematologic Malignancy", "Relapsed/Refractory Multiple Myeloma", "Relapsed/Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Caribou-sponsored investigational therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Caribou Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2022-03-16", "completion_date": "2041-12", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-11-15T18:54:17.878Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05332054" }, { "nct_id": "NCT00229203", "title": "A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Plitidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2005-02", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2009-12-24", "last_synced_at": "2026-11-15T18:54:17.878Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00229203" }, { "nct_id": "NCT05137054", "title": "A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Linvoseltamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Nirogacestat", "type": "DRUG" }, { "name": "Cevostamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2022-08-17", "completion_date": "2032-03-24", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-15T18:54:17.878Z", "location_count": 13, "location_summary": "La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05137054" }, { "nct_id": "NCT00003331", "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "1998-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-28", "last_synced_at": "2026-11-15T18:54:17.878Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003331" } ] }